An interventional study of Simeox and PARI O PEP in Primary Ciliary Dyskinesia, sponsored by University Hospital, Motol. Completed at 1 site in Czechia. Open to participants aged 4 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-03-02.
Sponsored by University Hospital, Motol · Not applicable, Interventional, and Supportive care
Primary ciliary dyskinesia (PCD) is characterized by impaired airway clearance and mucus stagnation. This results in recurrent upper and lower respiratory tract infections often leading to chronic inflammation and, if not treated early and properly, to irreversible functional and structural changes of the respiratory tract. As there is no causal treatment of PCD yet, airway clearance techniques (ACT) provide fundamental care for these patients.
Simeox is a new airway clearance device, recently developed by the French company PhysioAssist. This technology is based on pneumatic vibrations generated by the device itself. Vibrations are induced by rapidly alternating between atmospheric and negative pressure as the patient exhales, providing the most effective clearance of mucus from the lungs. Vibrations of different intensity and frequency are known to alter the rheological properties of mucus in the airways, whilst the negative pressure during exhalation helps to mobilise and drain the mucus to the central bronchi.
Although there have not yet been any evidence based papers published clarifying the effect of Simeox specifically in patients with PCD, using up-to-date information, experience, and positive feedback from our patients, we assume that there could be a significant benefit for the effectiveness of ACT.
In this study the effectiveness of ACT will be evaluated based on the short-term effect(s) of respiratory physiotherapy with Simeox on changes in lung function and thoracic expansibility paediatric patients with PCD.
An interventional randomised non-inferiority crossover trial will be conducted in Motol University Hospital; the project was developed by the multidisciplinary team (MDT) of the Division of Paediatric Pulmonology of the Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital; and the Department of Rehabilitation and Sports Medicine, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital.
Eligible patients will be randomly assigned into 2 arms - "Simeox-first group" and "Pari-O-PEP first" group. Randomisation will be done using computer generated code for each patient. The protocol will include 3 study visits - K0, K1 and K2 planned 3 months apart. After 6 months (second visit - K1), each patient will be switched to the other interventional group (crossed over). The first session (K0) includes an initial lung function assessment using spirometry, nitrogen-Multiple Breath Washout test (N2-MBW), Electrical Impedance Tomography (EIT), 6 Minute Walk Test (6 MWT), respiratory amplitudes (RA), and a theoretical introduction to therapy with the Simeox device. The second (K1) and third (K2) sessions will be interventional, including a respiratory physiotherapy session in between each measurement, excluding 6 MWT, which will be measured just once per session.
According to randomisation criteria, participants will initially undergo either physiotherapist-administered 20-minute ACT session using the Simeox device or 30-minute therapy with PARI O-PEP. In accordance with the rules for crossover study design, each patient will undergo therapy with both ACT devices, ideally within six-month duration of the study. These interventions will take place in between each measurement (spirometry, MBW, EIT, RA) during the second (K1) and the third (K2) session.
78 studies on the registry are indexed under Ciliary Motility Disorders; 26 are open to participants now.
This study's enrollment of 30 is close to the median of 32 across 24 interventional studies indexed under Ciliary Motility Disorders.
Browse Ciliary Motility Disorders studies →University Hospital, Motol is the lead sponsor of 45 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who will undergo Simeox intervention first. After three months cross-over to PARI O PEP intervention.
Device: Simeox
Patients who will undergo PARI O PEP intervention first. After three months cross-over to Simeox intervention.
Device: PARI O PEP
A respiratory physiotherapy session with the Simeox device will be performed in accordance with the official PhysioAssist recommendations, which are; * clearance of the upper airways before the physiotherapy session * correct position of the mouthpiece in patient's mouth, with the lips placed on the thinnest part of the mouthpiece and the tongue positioned underneath the mouthpiece * slow nasal inhalation without too much recruitment of the inspiratory residual volume (IRV) and an exhalation with real deflation of the thorax * step-by-step shifting of the patient's tidal volume towards the expiratory residual volume (ERV), in order to target the most distal regions of the lungs * comfortable, relaxed sitting position with straightened spine * controlled cough, which will be encouraged only when it is productive
ACT with PARI O-PEP will be performed in an upright sitting position, using four positions of the device for the most effective clearance of mucus from the lungs. These positions will be: * horizontal; * low; * transition of the device from the low position to the horizontal position; * upside down. The mouthpiece will be placed between the patient's teeth as per standard procedure, and enclosed properly within the lips. Patients will perform slow and deep inhalation via the nose, then hold their breath for about 1 to 2 seconds at the end of inhalation. Exhalation will be performed slowly and completely into the PARI O-PEP through the patient's mouth. At the end of the session, the patient will perform "huffing" with the PARI O-PEP device in the upside down position in order to maintain open airways, and, if possible, expectoration sputum.
Change in Lung Clearance Index
Ventilation Inhomogenity Assesment
Time frame: Through study completion, an average of 1 year
Change in Forced Residual Capacity (FRC)
Volume of air present in the lungs at the end of passive expiration, in Litres \[L\].
Time frame: Through study completion, an average of 1 year
Change in Forced Vital Capacity (FVC)
Volume of air that can forcibly be blown out after full inspiration, in Litres \[L\]
Time frame: Through study completion, an average of 1 year
Change in Forced Expiratory Volume in 1 second (FEV1)
Volume of air exhaled in the first second during forced exhalation after full inspiration, in Litres per second \[L/s\]
Time frame: Through study completion, an average of 1 year
Change in Maximal Expiratory Flow (MEF25-75)
Volume of air where the certain amount (25-75%) of Forced Vital Capacity (FVC) remains to be exhaled, in Litres \[L\]
Time frame: Through study completion, an average of 1 year
Change in Acinar airway inhomogeneity (Sacin)
MBW indices reflecting ventilation inhomogeneity in the acinar airway region, in Litres \[L\]
Time frame: Through study completion, an average of 1 year
Change in Conductive airway inhomogeneity (Scond)
MBW indices reflecting ventilation inhomogeneity in the conductive airway region, in Litres \[L\]
Time frame: Through study completion, an average of 1 year
Change in Global Inhomogeneity (GI) Index
Electrical Impedance Tomography parameter evaluating real-time spatial distribution of ventilation
Time frame: Through study completion, an average of 1 year
Change in chest expansion measurement
Chest expanson at axillary, mesosternal (mammary) and xiphosternal levels
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Motol